Abstract
Obesity occurs when energy expenditure is outweighed by energy intake. Tuberal hypothalamic nuclei, including the arcuate nucleus (ARC), ventromedial nucleus (VMH), and dorsomedial nucleus (DMH), control food intake and energy expenditure. Here we report that, in contrast with females, male mice lacking circadian nuclear receptors REV-ERBα and -β in the tuberal hypothalamus (HDKO mice) gained excessive weight on an obesogenic high-fat diet due to both decreased energy expenditure and increased food intake during the light phase. Moreover, rebound food intake after fasting was markedly increased in HDKO mice. Integrative transcriptomic and cistromic analyses revealed that such disruption in feeding behavior was due to perturbed REV-ERB-dependent leptin signaling in the ARC. Indeed, in vivo leptin sensitivity was impaired in HDKO mice on an obesogenic diet in a diurnal manner. Thus, REV-ERBs play a crucial role in hypothalamic control of food intake and diurnal leptin sensitivity in diet-induced obesity.
| Original language | English |
|---|---|
| Article number | e140424 |
| Journal | Journal of Clinical Investigation |
| Volume | 131 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 4 2021 |
Bibliographical note
Publisher Copyright:© 2021, American Society for Clinical Investigation.
Funding
We gratefully acknowledge L. Woodie for critically reading the manuscript. We thank L. Cheng from the Penn Molecular Pathology and Imaging Core for help with histology, as well as the Gene Expression and Functional Genomics Core of the Penn Diabetes Research Center (DK19525). This work was supported by NIH R01DK45586, the JPB Foundation, and the Cox Institute for Medical Research (to MAL). MA was supported by an American Diabetes Association Training grant (1-18-PDF-126). MRH was supported by NIH grant R01DKDK021397. Conflict of interest: MAL is an advisory board member for Eli Lilly and Pfizer Inc., consultant to Novartis, and receives research support from Pfizer. MRH has received research support from investigator-initiated sponsored proposals from Eli Lilly & Co. and Boehringer-Ingelheim. Copyright: © 2021, American Society for Clinical Investigation. Submitted: May 19, 2020; Accepted: September 29, 2020; Published: January 4, 2021. Reference information: J Clin Invest. 2021;131(1):e140424. https://doi.org/10.1172/JCI140424.
| Funders | Funder number |
|---|---|
| Cox Institute for Medical Research | |
| Eli Lilly & Co. and Boehringer-Ingelheim | |
| National Institutes of Health (NIH) | R01DK45586 |
| National Institutes of Health (NIH) | |
| American Diabetes Association Inc | 1-18-PDF-126, R01DKDK021397 |
| American Diabetes Association Inc | |
| National Institute of Diabetes and Digestive and Kidney Diseases | P30DK019525 |
| National Institute of Diabetes and Digestive and Kidney Diseases | |
| JPB Foundation |
ASJC Scopus subject areas
- General Medicine